FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2051857263> ?p ?o ?g. }

• W2051857263 endingPage "26856" @default.
• W2051857263 startingPage "26852" @default.
• W2051857263 abstract "S-Endo-1 antigen (CD146), a transmembrane receptor also known as MUC18/MCAM, is a member of the immunoglobulin superfamily and belongs to a group of cell adhesion molecules. CD146 is highly expressed on the whole vascular tree. We demonstrate here that engagement of CD146 on human endothelial cells isolated from cord blood results in tyrosine phosphorylation of a large panel of cellular proteins, although no tyrosine phosphorylation of CD146 was detected. In particular, CD146 cross-linking induces the tyrosine phosphorylation of the protein tyrosine kinase p125FAK as well as p125FAK association with paxillin, both events being inhibited by cytochalasin D. No direct association of CD146 with p125FAK was observed. Consistent with these data, CD146 associates with p59fyn, a Src family kinase known to phosphorylate p125FAK. The identification of a signaling pathway initiated by CD146 engagement and which includes p59fyn, p125FAK, and paxillin indicates that CD146 participates in outside-in signaling in endothelial cells. S-Endo-1 antigen (CD146), a transmembrane receptor also known as MUC18/MCAM, is a member of the immunoglobulin superfamily and belongs to a group of cell adhesion molecules. CD146 is highly expressed on the whole vascular tree. We demonstrate here that engagement of CD146 on human endothelial cells isolated from cord blood results in tyrosine phosphorylation of a large panel of cellular proteins, although no tyrosine phosphorylation of CD146 was detected. In particular, CD146 cross-linking induces the tyrosine phosphorylation of the protein tyrosine kinase p125FAK as well as p125FAK association with paxillin, both events being inhibited by cytochalasin D. No direct association of CD146 with p125FAK was observed. Consistent with these data, CD146 associates with p59fyn, a Src family kinase known to phosphorylate p125FAK. The identification of a signaling pathway initiated by CD146 engagement and which includes p59fyn, p125FAK, and paxillin indicates that CD146 participates in outside-in signaling in endothelial cells. human umbilical vein endothelial cell monoclonal antibody phosphotyrosine mouse monoclonal antibody against phosphotyrosine goat anti-mouse immunoglobulin peroxovanadate polyacrylamide gel electrophoresis protein tyrosine kinase constant variable. S-Endo-1 antigen (CD146) is an integral membrane protein present on human endothelial cells. It is identical to MUC18/MCAM, an antigen found on melanoma cells. CD146 is ubiquitously present on the endothelium along the whole vascular tree and is highly expressed on human umbilical vein endothelial cells (HUVECs)1 (1Bardin N. George F. Mutin M. Brisson C. Horschowski N. Francès V. Lesaule G. Sampol J. Tissue Antigens. 1996; 48: 531-539Crossref PubMed Scopus (125) Google Scholar, 2Bardin N. Francès V. Lesaule G. Horschowski N. George F. Sampol J. Biochem. Biophys. Res. Commun. 1996; 218: 210-216Crossref PubMed Scopus (114) Google Scholar). CD146 expression is not restricted to the endothelium; it is also detected in nonmalignant and malignant cells from other tissues (3Shih I.M. Elder D.E. Speicher D. Johnson J.P. Herlyn M. Cancer Res. 1994; 54: 2514-2520PubMed Google Scholar, 4Shih I.M. Kurman R. Lab. Invest. 1996; 75: 377-388PubMed Google Scholar, 5Pickl W.F. Majdic O. Fischer G.F. Petzelbauer P. Faé L. Waclavicek M. Stöckl J. Scheinecker C. Vidicki T. Aschauer H. Johnson J.P. Knapp W. J. Immunol. 1997; 158: 2107-2115PubMed Google Scholar, 6Shih I.E. Hsu M.Y. Palazzo J.P. Herlyn M. Am. J. Pathol. 1997; 151: 745-751PubMed Google Scholar, 7Shih I.M. Wang T.L. Westra W.H. Clin . Cancer Res. 1996; 2: 569-575PubMed Google Scholar). CD146 (113–119 kDa) is a highly glycosylated monomer that belongs to the immunoglobulin (Ig) superfamily of cell adhesion molecules (1Bardin N. George F. Mutin M. Brisson C. Horschowski N. Francès V. Lesaule G. Sampol J. Tissue Antigens. 1996; 48: 531-539Crossref PubMed Scopus (125) Google Scholar, 8Lehmann J.M. Holzmann B. Breitbart E.W. Schmiegelow P. Johnson J.P. Cancer Res. 1987; 47: 841-845PubMed Google Scholar,9Sers C. Kirsch K. Rothbächer U. Riethmüller G. Johnson J.P. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 8514-8518Crossref PubMed Scopus (127) Google Scholar). CD146 contains five extracellular Ig-like homology domains (V-V-C2-C2-C2), one transmembrane segment, and a short cytoplasmic tail (10Lehmann J.M. Riethmüller G. Johnson J.P. Proc. Natl. Acad. Sci. U. S. A. 1989; 86: 9891-9895Crossref PubMed Scopus (388) Google Scholar). CD146 molecular cloning has revealed significant homology to other Ig superfamily adhesion molecules such as B-CAM, ALCAM, BEN/DM-GRASP/SC1, KG-CAM, the chicken HEMCAM, and gicerin (11Taira E. Takaha N. Taniura H. Kim C.H. Miki N. Neuron. 1994; 12: 861-872Abstract Full Text PDF PubMed Scopus (91) Google Scholar, 12Campbell I.G. Foulkes W.D. Senger G. Trowsdale J. Garin-Chesa P. Rettig W.J. Cancer Res. 1994; 54: 5761-5765PubMed Google Scholar, 13Bowen M. Patel D.D. Li X. Modrell B. Malacko A.R. Wang W.C. Marquardt H. Neubauer M. Pesando J.M. Francke U. J. Exp. Med. 1995; 181: 2213-2220Crossref PubMed Scopus (322) Google Scholar, 14Laessing U. Giordano S. Stecher B. Lottspeich F. Stuemer C.A.O. Differentiation. 1996; 56: 21-29Crossref Scopus (59) Google Scholar, 15Peduzzi J.D. Irwin M.H. Giesert E.E. Brain Res. 1994; 640: 296-307Crossref PubMed Scopus (34) Google Scholar, 16Vaino O. Dunon D.L. Aissi F. Dangy J.P. McNagny K.M. Imhof B.A. J. Cell Biol. 1996; 135: 1655-1668Crossref PubMed Scopus (84) Google Scholar). CD146 function is still not elucidated, although recent data suggest its involvement in cell-cell adhesion. Indeed, the expression of CD146 on melanoma cells correlates with an invasive phenotype, indicating that CD146 may be used as a cell surface marker of tumor progression and metastasis formation (17Luca M. Hunt B. Bucana C.D. Johnson J.P. Fidler I.J. Bar-Eli M. Melanoma Res. 1993; 3: 35-41Crossref PubMed Scopus (112) Google Scholar, 18Sers C. Riethmüller G. Johnson J.P. Cancer Res. 1994; 54: 5689-5694PubMed Google Scholar, 19Xie S. Luca M. Huang S. Gutman M. Reich R. Johnson J. Cancer Res. 1997; 57: 2295-2303PubMed Google Scholar). Indeed, CD146 has been shown to be involved in tumor-endothelial cell interactions that might lead to extravasation of tumor cells (20Johnson J.P. Bar-Eli M. Jansen B. Markhof E. Int. J. Cancer. 1997; 73: 769-774Crossref PubMed Google Scholar, 21Shih I.E. Speicher D. Hsu D. Levine E. Herlyn M. Cancer Res. 1997; 57: 3835-3840PubMed Google Scholar). Finally, it has been reported that CD146 mediates a Ca2+-independent homotypic melanoma cell adhesion by promoting heterophilic interaction through a still unknown ligand (19Xie S. Luca M. Huang S. Gutman M. Reich R. Johnson J. Cancer Res. 1997; 57: 2295-2303PubMed Google Scholar, 21Shih I.E. Speicher D. Hsu D. Levine E. Herlyn M. Cancer Res. 1997; 57: 3835-3840PubMed Google Scholar). CD146 is located at the interendothelial junctions. It is found in cytoskeletal protein-rich fractions and colocalizes with α-actinin (22Ming I.E. Elder D.E. Speicher D. Johnson J.P. Herlyn M. Cancer Res. 1994; 54: 2514-2520PubMed Google Scholar). 2N. Bardin, V. Francès, J. Sampol, and F. Dignat-George, manuscript in preparation.2N. Bardin, V. Francès, J. Sampol, and F. Dignat-George, manuscript in preparation. It is well documented that proteins present at the interendothelial junctions promote adhesion through their extracellular domain and mediate intracellular signaling to the complex network of cytoskeletal proteins through their intracytoplasmic part (23Lampugnani M.G. Dejana E. Curr. Opin. Cell Biol. 1997; 9: 674-682Crossref PubMed Scopus (197) Google Scholar). CD146 possesses potential recognition sites for protein kinases in its cytoplasmic tail (9Sers C. Kirsch K. Rothbächer U. Riethmüller G. Johnson J.P. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 8514-8518Crossref PubMed Scopus (127) Google Scholar) which might be involved in signal transduction. Nevertheless, CD146 involvement in outside-in signaling in HUVECs has not been investigated. In this present report, we investigated the signaling pathways initiated by CD146 engagement. Because the ligand of CD146 is unknown, CD146 clustering was performed using anti-CD146 monoclonal antibody (mAb) on HUVECs. Results indicate that cross-linking of CD146 induces tyrosine phosphorylation of a large panel of proteins, among which p125FAK and paxillin associate with each other. However, CD146 is not directly bound to these proteins but becomes associated with p59fyn. Thus, our results indicate that CD146 engagement may initiate a reorganization of the cytoskeleton through a p59fyn- and p125FAK-dependent pathway. The following mAbs and polyclonal antibodies were used: S-Endo-1 (F(ab′)2 fragment) and 7A4 mAbs, both specific for CD146 and kindly given by Biocytex (Marseilles, France); anti-Tyr(P) 4G10 (Upstate Biotechnology, Lake Placid, NY) and PY20 (Transduction Laboratories, Lexington, KY) mAbs; anti-p125FAK, anti-paxillin, anti-p53/56lyn, p59fyn mAbs (Transduction Laboratories); rabbit anti-p72syk (kindly given by Dr. R. Geahlen, IN); isotype-matched IgG1 or IgG2a (Sigma, St. Louis, MO); horseradish peroxidase-labeled goat anti-rabbit, goat anti-mouse (GAMIg) and its F(ab′)2 fragment (Jackson laboratories, Palo Alto, CA). HUVECs were isolated from cord blood (24Jaffe E. Nachman R. Becker C. Minick C. J. Clin. Invest. 1973; 52: 2745-2756Crossref PubMed Scopus (5968) Google Scholar). They were used at confluence after one passage. They were rendered quiescent by incubation in RPMI 1640 medium containing 1% fetal calf serum 2 h before cell activation. Quiescent HUVECs were incubated in Hanks' balanced salt solution for 30 min at 4 °C with either isotype-matched IgG1 (control cells) or 10 μg/ml S-Endo-1 F(ab′)2 mAb for CD146 clustering; when indicated, cells were further stimulated with 20 μg/ml F(ab′)2 GAMIg for 30 min at 37 °C. After three washes at 4 °C, the cells were lysed for immunoblotting. Genistein, Herbimycin, and Cytochalasin D (Alexis, San Diego, CA) were used at 50, 10, and 5 μm, respectively. HUVECs were incubated with the drugs in serum-free Hanks' balanced salt solution 1 h before the clustering of CD146 with S-Endo-1 mAb. Peroxovanadate (NaV) was generated as described previously (25Donnadieu E. Trautmann A. Malissen M. Trucy J. Malissen B. Vivier E. J. Biol. Chem. 1994; 269: 32828-32834Abstract Full Text PDF PubMed Google Scholar). HUVECs were incubated in presence of a 100 μm NaV solution for up to 15 min. After activation, the cells were lysed at 4 °C in 500 μl of lysis buffer (10 mm Tris-HCl, pH 7.5, 150 mm NaCl, 2 mm EDTA, 1% Nonidet P-40, 2 mm sodium orthovanadate, 50 mm sodium fluoride, 1 mm phenylmethylsulfonyl fluoride, 25 μg/ml aprotinin, 2 μg/ml leupeptin, 2 μg/ml pepstatin). After adjustment to a protein concentration of 300–500 μg, i.e. 3–6 × 106 cells (bicinchoninic acid assay, Pierce, Rockford, IL), cell lysates were precleared by incubation with irrelevant IgG1 or IgG2a mAbs and protein G-Sepharose (Pharmacia Biotech, Uppsala, Sweden) for 1 h at 4 °C. Precleared samples were immunoprecipitated with 2 μg for 3 h at 4 °C followed by a 2-h incubation with protein G-Sepharose. Immunoprecipitates were analyzed by SDS-PAGE and immunoblotting. Immunoprecipitations using anti-CD146 and anti-Tyr(P) were performed, respectively, with S-Endo-1 and 4G10 mAbs. Immunoprecipitates or total cell lysates were subjected to SDS-PAGE and transferred to nitrocellulose C+ filters. After blocking in 10 mm Tris-HCl buffer, pH 7.5, 0.15 m NaCl, 0.1% Tween 20, 3% bovine serum albumin (TBS-T BSA), they were incubated in TBS-T BSA containing protein-specific antibodies (1 μg/ml) for 1 h at room temperature. Immunoreactive bands were visualized by chemiluminescence using horseradish peroxidase-conjugated anti-mouse or rabbit IgG and ECL reagent. Western blotting using anti-CD146 was performed with 7A4 mAb. When required, membranes were stripped in 62.5 mmTris-HCl, pH 6.8, 2 mm EDTA, 2% SDS, 100 mmβ-mercaptoethanol for 30 min at 60 °C and reblotted with the indicated antibodies. Engagement of CD146 was obtained by incubating HUVECs with S-Endo-1 F(ab′)2 mAb and subsequently by cross-linking the complexes with GAMIg. Whole cell lysates were analyzed on a 5–15% gradient SDS-PAGE followed by immunoblotting with anti-Tyr(P) mAb. In HUVECs, engagement of CD146 induced the tyrosine phosphorylation of a large panel of proteins (Fig. 1, lane 2), which was increased further upon cross-linking with GAMIg at 37 °C for 30 min (Fig. 1, lane 3). The complex pattern of tyrosine-phosphorylated proteins consistently includes proteins at apparent molecular masses of 46, 55–60, 70–80, 100, 125, and 150 kDa. A 2-h pretreatment of HUVEC with 50 μm genistein (Fig. 1,lane 4) or 2 μm herbimycin (Fig. 1, lane 5) greatly reduced the tyrosine phosphorylation induced by CD146 engagement. Kinetic analysis of the induction of tyrosine phosphorylation upon CD146 engagement revealed a rapid onset after 5 min, a maximum at 30 min, followed by a decrease thereafter (data not shown). In contrast, in HUVECs treated with a control isotype-matched (IgG1) antibody cross-linked with GAMIg, a pattern of constitutive tyrosine phosphorylation was barely detectable (Fig. 1, lane 1). The presence of a tyrosine residue at position 641 (Tyr-Ile-Asp-Leu) in CD146 cytoplasmic tail suggests a potential site of phosphorylation of the molecule (9Sers C. Kirsch K. Rothbächer U. Riethmüller G. Johnson J.P. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 8514-8518Crossref PubMed Scopus (127) Google Scholar). The capacity of CD146 engagement to phosphorylate Tyr641 was studied. As shown in Fig. 2 (upper panel), anti-Tyr(P) immunoblotting of anti-CD146 immunoprecipitation revealed that CD146 is not tyrosine-phosphorylated, either in isotype-matched control (lane 1) or in CD146-stimulated cells (lane 2). Reciprocal experiments, using anti-CD146 immunoblotting of anti-Tyr(P) immunoprecipitation, led to similar results (Fig. 2, upper panel, lane 4). As a control, immunoprecipitation and immunoblotting with anti-CD146 mAbs revealed the presence of CD146 in these samples (Fig. 2, lower panel). NaV is a potent inducer of tyrosine phosphorylation (25Donnadieu E. Trautmann A. Malissen M. Trucy J. Malissen B. Vivier E. J. Biol. Chem. 1994; 269: 32828-32834Abstract Full Text PDF PubMed Google Scholar) and was tested for its ability to promote tyrosine phosphorylation of CD146. HUVECs were treated with 0.1 mm NaV for 15 min and lysed. No tyrosine phosphorylation in the molecular weight range of CD146 was observed in anti-Tyr(P) immunoblots of anti-CD146 immunoprecipitates (Fig. 2, lane 3), although CD146 was present in the cell lysate after reblotting. The lack of tyrosine phosphorylation in CD146 was observed irrespective of the dose of NaV (0.2–3 mm) and time of incubation (2–30 min) used in the experiments (data not shown). The colocalization of CD146 with cytoskeletal proteins2 and the tyrosine phosphorylation of a band in the molecular weight range of 125,000 suggested that p125FAK could be tyrosine-phosphorylated upon CD146 engagement (26Schaller M.D. Borgman C.A. Cobb B.S. Vines R.R. Reynolds A.B. Parsons J.T. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 5192-5196Crossref PubMed Scopus (1280) Google Scholar). To examine whether CD146 engagement stimulates tyrosine phosphorylation of p125FAK in HUVECs, cell lysates were immunoprecipitated with anti-p125FAK mAb and immunoblotted with anti-Tyr(P) mAb. Fig. 3 A shows that a constitutive tyrosine phosphorylation of p125FAK occurs in isotype-matched control cells (lane 1). CD146 engagement caused a marked increase in the tyrosine phosphorylation of p125FAK (Fig. 3A, lane 2). Disruption of the actin network by a 2-h pretreatment of the HUVEC monolayer with 5 μm cytochalasin D inhibited the p125FAKtyrosine phosphorylation mediated by CD146 clustering (Fig. 3 A, lane 3).Figure 4Association of CD146 with p59 fyn . CD146 engagement was performed as described under “Experimental Procedures.” Lysates (500 μg) were immunoprecipitated using S-Endo-1 mAb. Immunoprecipitates were first immunoblotted with the indicated anti-PTK antibodies (upper panel) and reblotted with 7A4 mAb (lower panel).View Large Image Figure ViewerDownload Hi-res image Download (PPT) A direct association between CD146 and p125FAK was investigated in response to CD146 engagement. Cell lysates were immunoprecipitated with anti-CD146 and immunoblotted with anti-p125FAK. No protein in the molecular mass range of ≈125 kDa was detected (Fig. 3 B, upper panel), although reprobing with anti-CD146 mAb indicated that CD146 was present in anti-CD146 immunoprecipitates (Fig. 3 B, lower panel). These results showed that CD146 cross-linking induces p125FAKphosphorylation but does not induce an association between CD146 and p125FAK. Tyrosine phosphorylation of paxillin, a substrate for p125FAK (27Calalb M.B. Polte T.R. Hanks S.K. Mol. Cell. Biol. 1995; 15: 954-963Crossref PubMed Google Scholar), and its association with p125FAKwere investigated in response to CD146 engagement. Results in Fig. 3 C indicate that CD146 cross-linking induces tyrosine phosphorylation of a protein in the range of ≈70 kDa detected by anti-paxillin mAb after immunoprecipitation with anti-Tyr(P) (lane 1). Association of paxillin with p125FAKwas then examined. Detection of paxillin in anti-p125FAKimmunoprecipitates was observed after CD146 engagement (Fig. 3 C, lane 3) and was not revealed in lysates from cells stimulated with isotype-matched control mAb (Fig. 3 C, lane 2). A 2-h treatment of HUVECs with 5 μmcytochalasin D before CD146 cross-linking inhibits paxillin association with p125FAK entirely (Fig. 3 C, lane 4). Because CD146 engagement induces the tyrosine phosphorylation of p125FAK and paxillin, we investigated whether CD146 engagement results in the recruitment of PTK(s) in the vicinity of CD146. In this regard, p125FAK possesses several binding sites for Src or Src-related kinases (26Schaller M.D. Borgman C.A. Cobb B.S. Vines R.R. Reynolds A.B. Parsons J.T. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 5192-5196Crossref PubMed Scopus (1280) Google Scholar). In addition, CD146 engagement induces tyrosine phosphorylation of proteins with molecular masses (≈55–80 kDa) close to those of Src-related kinases such as p53/56lyn and p59fyn, as well as other PTKs such as p72syk, all known to bind p125FAK. We next determine whether these PTKs are involved in CD146 signal pathway. No association between p53/56lyn or p72syk with CD146 was detected (Fig. 4, upper panel), although reprobing with anti-CD146 mAb confirmed the presence of CD146 in anti-CD146 immunoprecipitates (Fig. 4, lower panel). These results indicated that CD146 cross-linking induces the recruitment of p59fyn kinase to CD146. The results reported here demonstrate that in cultured HUVECs, engagement of CD146 initiates a PTK-dependent signaling cascade. Activation of this pathway results in the tyrosine phosphorylation of a complex pattern of proteins, including p125FAK and paxillin as well as the association of p59fyn with CD146. To our knowledge, this is the first report demonstrating an outside-in signaling pathway downstream of CD146. Dimerization of cell surface receptors represents a key event in signal transduction (28Schlessinger J. Cell. 1997; 91: 869-872Abstract Full Text Full Text PDF PubMed Scopus (72) Google Scholar). Binding of S-Endo-1 mAb to the extracellular part of CD146 induces a dimerization of CD146 sufficient to promote the tyrosine phosphorylation of intracellular proteins. Cross-linking of CD146 dimers by a secondary antibody leads to an oligomerization of CD146 which subsequently increases the intensity of the phosphorylation events. This process is time- and dose-dependent and requires genistein- and herbimycin-sensitive kinases. Phosphorylation of tyrosine residues plays an important role in signal transduction by creating docking sites for SH2 domains of signaling molecules (29Koch C.A. Anderson D. Moran M.F. Ellis C. Pawson T. Science. 1991; 252: 668-674Crossref PubMed Scopus (1427) Google Scholar). Although the CD146 molecule contains a tyrosine residue (Tyr641) in its cytoplasmic tail (10Lehmann J.M. Riethmüller G. Johnson J.P. Proc. Natl. Acad. Sci. U. S. A. 1989; 86: 9891-9895Crossref PubMed Scopus (388) Google Scholar), we cannot detect any tyrosine phosphorylation of CD146 upon anti-CD146 mAb or upon NaV treatment. These results indicate that CD146 does not serve as a docking site for an SH2 adaptor/effector signaling molecule. We also show here that upon aggregation, CD146 associates with p59fyn, a nonreceptor PTK belonging to the Src family kinases (30Kypta R.M. Hemming A. Courtneidge S.A. EMBO J. 1988; 7: 3837-3844Crossref PubMed Scopus (105) Google Scholar). p59Fyn possesses adjacent Src homology SH2 and SH3 domains involved in the binding to target proteins (31Panchamoorthy G. Fukazawa T. Stolz L. Payne G. Reedquist K. Shoelson S. Zhou S. Cantley L. Walsh C. Band H. Mol. Cell. Biol. 1994; 14: 6372-6385Crossref PubMed Scopus (58) Google Scholar). The lack of tyrosine-phosphorylable CD146 excludes the binding by the SH2 domain of p59fyn(32Small S.J. Shull G.E. Santioni M.J. Akeson R. J. Cell Biol. 1987; 105: 2335-2345Crossref PubMed Scopus (92) Google Scholar). In an other way, it is known that the SH3 domains bind to a proline-rich sequence. Although the CD146 cytoplasmic tail contains proline residues, no consensus sequence for SH3 binding site is found (33Pawson T. Scott J.D. Science. 1997; 278: 2075-2080Crossref PubMed Scopus (1883) Google Scholar). Therefore, the molecular basis of the p59fyn interaction with CD146 is still unknown. Consistent with the recruitment of p59Fyn to the membrane upon CD146 engagement, we observe the tyrosine phosphorylation of two major proteins involved in the formation of focal adhesion plaques, p125FAK and paxillin. These results indicate that CD146 cross-linking induces downstream events that activate p125FAK and mediate its association with its substrates such as paxillin. Both p125FAK tyrosine phosphorylation and its association with paxillin depend on the integrity of the cytoskeleton as they are inhibited by pretreatment of cytochalasin D (34Seufferlein T. Rozengurt E. J. Biol. Chem. 1994; 269: 9345-9351Abstract Full Text PDF PubMed Google Scholar). It is well known that p125FAK possesses high affinity binding sites for members of Src family kinases, including p59fyn, which in turn can phosphorylate other tyrosines on p125FAK (26Schaller M.D. Borgman C.A. Cobb B.S. Vines R.R. Reynolds A.B. Parsons J.T. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 5192-5196Crossref PubMed Scopus (1280) Google Scholar). p59fyn participates in the phosphorylation of Tyr at positions 397, 576, 577, and 925, present in the catalytic and COOH-terminal domains of p125FAK (27Calalb M.B. Polte T.R. Hanks S.K. Mol. Cell. Biol. 1995; 15: 954-963Crossref PubMed Google Scholar, 35Schaller M.D. Hildebrand J.D. Shannon J.D. Fox J.W. Vines R.R. Parsons J.T. Mol. Cell. Biol. 1994; 14: 1680-1688Crossref PubMed Scopus (1113) Google Scholar,36Calalb M.B. Zhang X. Polte T.R. Hanks S.K. Biochem. Biophys. Res. Commun. 1996; 228: 662-668Crossref PubMed Scopus (193) Google Scholar). These phosphorylations create multiple binding sites for substrate proteins (26Schaller M.D. Borgman C.A. Cobb B.S. Vines R.R. Reynolds A.B. Parsons J.T. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 5192-5196Crossref PubMed Scopus (1280) Google Scholar, 38Schaller M.D. J. Endocrinol. 1996; 150: 1-7Crossref PubMed Scopus (74) Google Scholar) including paxillin, tensin, and p130Cas(39Turner C.E. Glenney J.R. Burridge K. J. Cell Biol. 1990; 111: 1059-1068Crossref PubMed Scopus (522) Google Scholar, 40Lo S.H. Weisberg E. Chen L.B. Bioessays. 1994; 16: 817-823Crossref PubMed Scopus (117) Google Scholar, 41Petch L.A. Bockholt S.M. Bouton A. Parsons J.T. Burridge K. J. Cell Sci. 1995; 108: 1371-1379Crossref PubMed Google Scholar). Paxillin is a cytoskeletal protein that localizes to sites of adhesion and binds to two sequences present in the carboxyl terminus of p125FAK (42Hildebrand J.D. Schaller M.D. Parsons J.T. Mol. Biol. Cell. 1995; 6: 637-647Crossref PubMed Scopus (306) Google Scholar, 43Brown M.C. Perrotta J.A. Turner C.E. J. Cell Biol. 1996; 135: 1109-1123Crossref PubMed Scopus (296) Google Scholar). Its association with p125FAKis thought to modulate the localization of p125FAK to focal adhesion plaques (44Turner C.E. Schaller M.D. Parsons J.T. J. Cell Sci. 1993; 105: 637-645Crossref PubMed Google Scholar, 45Bellis S.L. Miller J.T. Turner C.E. J. Biol. Chem. 1995; 270: 17437-17441Abstract Full Text Full Text PDF PubMed Scopus (298) Google Scholar, 46Tachibana K. Sato T. D'Aviro N. Morimoto C. J. Exp. Med. 1995; 182: 1089-1099Crossref PubMed Scopus (237) Google Scholar). Taken together, the results suggest that CD146 engagement mediates the formation of a complex among CD146, p59fyn, p125FAK, and paxillin, which promotes focal adhesion assembly. It is tempting to speculate that CD146 engagement does not only involve an outside-in PTK pathway in HUVEC but also initiates an inside-out PTK-dependent signaling pathway. In mice, p125FAK gene inactivation impairs cell motility (47Illic D. Furuta Y. Kanazawa S. Takeda N. Sobue K. Nakatsuji N. Nomura S. Fujimoto J. Okada M. Yamamoto T. Alzawa S. Nature. 1995; 377: 539-544Crossref PubMed Scopus (1576) Google Scholar), whereas its overexpression stimulates cell migration (48Cary L.A. Chang J.F. Guan J.L. J. Cell Sci. 1996; 109: 1787-1794Crossref PubMed Google Scholar). In addition, p125FAK and paxillin phosphorylations are increased by cell density (37Batt D.B. Roberts T.M. J. Biol. Chem. 1998; 273 (s): 3408-3414Abstract Full Text Full Text PDF PubMed Scopus (41) Google Scholar). Preliminary results2 indicate that CD146 expression on the plasma membrane is also increased by cell density. CD146 might therefore participate in the establishment of the endothelial monolayer by initiating downstream events that promote cell proliferation and monolayer formation. Taken together, the data presented here indicate a role of CD146 in signaling. They suggest that interaction of CD146 with its still unknown ligand might lead to a similar signaling pathway. We thank Anny Bottary, Andrée Boyer and Patricia Stellmann for skillful technical assistance and Corinne Beziers La Fosse (CIML, Marseille, France) for assistance in preparing figures. We are grateful to the Biocytex company for providing 7A4 mAb and S-Endo-1 F(ab′)2 fragment." @default.
• W2051857263 created "2016-06-24" @default.
• W2051857263 creator A5018259733 @default.
• W2051857263 creator A5023634131 @default.
• W2051857263 creator A5032811789 @default.
• W2051857263 creator A5039736912 @default.
• W2051857263 creator A5057904192 @default.
• W2051857263 creator A5071181103 @default.
• W2051857263 creator A5085151012 @default.
• W2051857263 date "1998-10-01" @default.
• W2051857263 modified "2023-09-30" @default.
• W2051857263 title "Activation of Human Endothelial Cells via S-Endo-1 Antigen (CD146) Stimulates the Tyrosine Phosphorylation of Focal Adhesion Kinase p125FAK" @default.
• W2051857263 cites W1493689654 @default.
• W2051857263 cites W1592758533 @default.
• W2051857263 cites W168147921 @default.
• W2051857263 cites W1956645860 @default.
• W2051857263 cites W1969142649 @default.
• W2051857263 cites W1969689864 @default.
• W2051857263 cites W1972172786 @default.
• W2051857263 cites W1977199477 @default.
• W2051857263 cites W1978635034 @default.
• W2051857263 cites W1991015390 @default.
• W2051857263 cites W1996418299 @default.
• W2051857263 cites W1999996757 @default.
• W2051857263 cites W2019756108 @default.
• W2051857263 cites W2025018535 @default.
• W2051857263 cites W2028691987 @default.
• W2051857263 cites W2038816853 @default.
• W2051857263 cites W2041583420 @default.
• W2051857263 cites W2045148822 @default.
• W2051857263 cites W2048500186 @default.
• W2051857263 cites W2054498037 @default.
• W2051857263 cites W2058170261 @default.
• W2051857263 cites W2072188162 @default.
• W2051857263 cites W2075108645 @default.
• W2051857263 cites W2077980654 @default.
• W2051857263 cites W2081135891 @default.
• W2051857263 cites W2088855030 @default.
• W2051857263 cites W2095338040 @default.
• W2051857263 cites W2101433730 @default.
• W2051857263 cites W2105356859 @default.
• W2051857263 cites W2116312858 @default.
• W2051857263 cites W2133613849 @default.
• W2051857263 cites W2150980909 @default.
• W2051857263 cites W2156451315 @default.
• W2051857263 cites W2157603347 @default.
• W2051857263 cites W2395438838 @default.
• W2051857263 cites W2407432304 @default.
• W2051857263 cites W4232924472 @default.
• W2051857263 cites W4249092084 @default.
• W2051857263 doi "https://doi.org/10.1074/jbc.273.41.26852" @default.
• W2051857263 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9756930" @default.
• W2051857263 hasPublicationYear "1998" @default.
• W2051857263 type Work @default.
• W2051857263 sameAs 2051857263 @default.
• W2051857263 citedByCount "92" @default.
• W2051857263 countsByYear W20518572632012 @default.
• W2051857263 countsByYear W20518572632013 @default.
• W2051857263 countsByYear W20518572632014 @default.
• W2051857263 countsByYear W20518572632015 @default.
• W2051857263 countsByYear W20518572632016 @default.
• W2051857263 countsByYear W20518572632017 @default.
• W2051857263 countsByYear W20518572632018 @default.
• W2051857263 countsByYear W20518572632019 @default.
• W2051857263 countsByYear W20518572632020 @default.
• W2051857263 countsByYear W20518572632021 @default.
• W2051857263 countsByYear W20518572632022 @default.
• W2051857263 countsByYear W20518572632023 @default.
• W2051857263 crossrefType "journal-article" @default.
• W2051857263 hasAuthorship W2051857263A5018259733 @default.
• W2051857263 hasAuthorship W2051857263A5023634131 @default.
• W2051857263 hasAuthorship W2051857263A5032811789 @default.
• W2051857263 hasAuthorship W2051857263A5039736912 @default.
• W2051857263 hasAuthorship W2051857263A5057904192 @default.
• W2051857263 hasAuthorship W2051857263A5071181103 @default.
• W2051857263 hasAuthorship W2051857263A5085151012 @default.
• W2051857263 hasConcept C10205521 @default.
• W2051857263 hasConcept C11960822 @default.
• W2051857263 hasConcept C151166631 @default.
• W2051857263 hasConcept C178790620 @default.
• W2051857263 hasConcept C185592680 @default.
• W2051857263 hasConcept C2777553839 @default.
• W2051857263 hasConcept C2779093498 @default.
• W2051857263 hasConcept C28328180 @default.
• W2051857263 hasConcept C502942594 @default.
• W2051857263 hasConcept C84416704 @default.
• W2051857263 hasConcept C86803240 @default.
• W2051857263 hasConcept C95444343 @default.
• W2051857263 hasConceptScore W2051857263C10205521 @default.
• W2051857263 hasConceptScore W2051857263C11960822 @default.
• W2051857263 hasConceptScore W2051857263C151166631 @default.
• W2051857263 hasConceptScore W2051857263C178790620 @default.
• W2051857263 hasConceptScore W2051857263C185592680 @default.
• W2051857263 hasConceptScore W2051857263C2777553839 @default.
• W2051857263 hasConceptScore W2051857263C2779093498 @default.
• W2051857263 hasConceptScore W2051857263C28328180 @default.
• W2051857263 hasConceptScore W2051857263C502942594 @default.
• W2051857263 hasConceptScore W2051857263C84416704 @default.

• next